Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HTR2B | P41595 | 6/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CXCR6 | O00574 | 1/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.42 |
| ▸ | GID4 | Q8IVV7 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13490619 | 0.87 | CXCR6 (0.42) | HTR2BSMN1; SMN2CXCR6USP30GID4 | |
| Hydrochloric Acid SCHEMBL3224045 | 0.86 | CXCR6 (0.42) | HTR2BSMN1; SMN2CXCR6USP30GID4 | |
| SCHEMBL13490374 | 0.85 | GRM5 (0.53) | ALDH1A1HTR2BSMN1; SMN2CXCR6 | |
| SCHEMBL13490582 | 0.85 | FOXO1 (0.50) | ALDH1A1HTR2BSMN1; SMN2CXCR6 | |
| Hydrochloric Acid SCHEMBL3199346 | 0.84 | GRM5 (0.53) | ALDH1A1HTR2BSMN1; SMN2CXCR6 | |
| SCHEMBL13490663 | 0.84 | SMN1; SMN2 (0.47) | HTR2BSMN1; SMN2CXCR6GID4 | |
| SCHEMBL14192836 | 0.83 | CHEK1 (0.46) | HTR2BSMN1; SMN2CXCR6USP30GID4 | |
| SCHEMBL3212293 | 0.83 | HCAR3 (0.45) | ALDH1A1HTR2BCXCR6GID4 | |
| SCHEMBL14192261 | 0.83 | HCAR3 (0.45) | ALDH1A1HTR2BCXCR6GID4 | |
| SCHEMBL13490400 | 0.82 | HTR2B (0.56) | ALDH1A1HTR2BSMN1; SMN2CXCR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029615-A1 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. | 2010-02-04 | — | — | US | disclosed |
| EP-2121626-A1 | BENZIMIDAZOLE DERIVATIVES | Pfizer Products Inc. (US) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008075196-A1 | BENZIMIDAZOLE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029615-A1 | BENZIMIDAZOLE DERIVATIVES | ACIN1, HAT1, CCNE1 | ALDH1A1 680/4885HTR2B 3456/4885SMN1; SMN2 746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.